Such rapid‐onset, non‐IgE‐mediated toxicity challenges conventional risk stratification models that prioritize allergy history (OR = 2.232) and classical symptoms (75.4% pruritus, 60% dyspnea prevalence) [17]. This evidence concerns the gene IGHE and allergic disease.